Change Condition
Patients HCP
This site is for US residents only.

For adults with moderate to severe hidradenitis suppurativa

Purple to pink gradient background

COSENTYX® (secukinumab) IS PROVEN TO REDUCE HS SYMPTOMS IN REAL PEOPLE

50% of reduction in abscesses and no increase in these symptoms

In the 2 clinical trials, 41% and 43% of adults taking COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses) had at least a 50% reduction in the number of inflammatory bumps and abscesses with no increase in the number of abscesses and/or draining tunnels at 16 weeks vs 29% and 26% taking placebo.

In the 2 clinical trials, 41% and 43% of adults taking COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses) had at least a 50% reduction in the number of inflammatory bumps and abscesses, with no increase in the number of abscesses and/or draining tunnels at 16 weeks vs 29% and 26% taking placebo.

75% of people had zero flares at 16 weeks

In 1 of 2 clinical trials, 75% of adults taking COSENTYX had zero flares at week 16. In the same clinical trial, 25% of adults taking COSENTYX had 1 or more flares at week 16 vs 36% taking placebo. In the second trial, the same results were not seen. A flare was defined as a greater than 25% increase in the number of inflammatory bumps and abscesses, with a minimum increase of 2 inflammatory bumps or abscesses.

In 1 of 2 clinical trials, 75% of adults taking COSENTYX† had zero flares at week 16. In the same clinical trial, 25% of adults taking COSENTYX had 1 or more flares at week 16 vs 36% taking placebo. In the second trial, the same results were not seen. A flare was defined as a greater than 25% increase in the number of inflammatory bumps and abscesses, with a minimum increase of 2 inflammatory bumps or abscesses.

†COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses).

People saw symptom improvement in as early as 2 weeks

People saw symptom improvement in as early as 2 weeks. These results were from a less rigorous analysis, so it is not known if symptom improvement was due to COSENTYX. Everyone’s experience is different.

These results were from a less rigorous analysis, so it is not known if symptom improvement was due to COSENTYX. Everyone's experience is different.

Improvements in HS symptoms over 1 year

In the 2 clinical trials, at 1 year, 58% and 65% had at least a 50% reduction in the number of abscesses and/or draining tunnels. In addition, 72% and 74% did not experience a flare. In the clinical trials, a flare was defined as a greater than 25% increase in the number of inflammatory bumps and abscesses. These results were from a less rigorous analysis, so it is not known if symptom improvement was due to COSENTYX. Everyone’s experience is different.
  • People taking COSENTYX® maintained the reduction of bumps and abscesses
  • An average of 61% saw no increase in draining tunnels
  • An average of 73% had zero flares

 

In the 2 clinical trials, at 1 year, 58% and 65% had at least a 50% reduction in the number of abscesses and/or draining tunnels. In addition, 72% and 74% did not experience a flare. In the clinical trials, a flare was defined as a greater than 25% increase in the number of inflammatory bumps and abscesses. 

 

These results were from a less rigorous analysis, so it is not known if symptom improvement was due to COSENTYX. Everyone's experience is different.

Continued results at 2 years

People taking COSENTYX® maintained the reduction of bumps and abscesses. In an extension study, which followed patients from two clinical trials, 76.5% and 87.5% of patients who had previously experienced at least a 50% reduction in the number of inflammatory bumps and abscesses, with no increase in the number of abscesses and/or draining tunnels at Year 1 maintained this reduction at Year 2. Because these results were from a less rigorous analysis, no conclusions can be drawn.

People taking COSENTYX® maintained the reduction of bumps and abscesses.
 

In an extension study, which followed patients from two clinical trials, 76.5% and 87.5% of patients who had previously experienced at least a 50% reduction in the number of inflammatory bumps and abscesses, with no increase in the number of abscesses and/or draining tunnels at Year 1 maintained this reduction at Year 2.‡ Because these results were from a less rigorous analysis, no conclusions can be drawn.

‡Results are from a 300 mg dose of COSENTYX every 2 weeks or every 4 weeks respectively. Results may vary. Everyone responds to treatment differently.
“I struggled with HS for years. With less bumps and abscesses, I got this.” - Frank Grimsley

Individual results may vary. Frank was compensated for his time.

"I struggled with HS for years. With less bumps and abscesses, I got this."


- Frank Grimsley

Get specific about your HS symptoms.

Learn how to share the details of your HS symptoms with your doctor.

Start Here
*Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions for details.